Belenos Biosciences
Phase 3We believe that clinical remission should be the standard—not the exception—for treating chronic inflammatory diseases like COPD, asthma and atopic dermatitis. Our bispecific therapeutics are designed to target proven disease pathways, with the goal of delivering meaningful, lasting outcomes for patients.
Founded
2016
Focus
AntibodiesBiologics
About
We believe that clinical remission should be the standard—not the exception—for treating chronic inflammatory diseases like COPD, asthma and atopic dermatitis. Our bispecific therapeutics are designed to target proven disease pathways, with the goal of delivering meaningful, lasting outcomes for patients.
Funding History
2Total raised: $25M
Series A$20MUndisclosedNov 15, 2022
Seed$5MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2016
LocationSan Diego, United States
StagePhase 3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile